Clinical Trials

NCT IdNCT04872218
TitleAdjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy
ConditionPeanut Allergy
StudyTypeInterventional
OrganizationSt. Justine's Hospital
Sponsor/CollaboratorsPhilippe Bégin
StatusNot yet recruiting
GenderAll
AgeGroupChild
Adult
Location (with distance)
DescriptionThis is a phase 2a, multi-center, randomized and double-blind placebo-controlled trial comparing 24 weeks of abatacept versus placebo used as adjuvant to oral immunotherapy to induce remission in adolescents and adults with persistent severe peanut allergy. This is a proof-of-concept trial in which the primary outcome will be the suppression of the initial peanut specific IgE surge during OIT, which is used as a proxy outcome of peanut allergy remission. Adolescents and adults with persistent severe peanut allergy (n=14) will be randomized to either abatacept or placebo at a ratio 1:1 for a total period of 24 weeks. Peanut oral immunotherapy will be initiated the day following the first administration of the investigational product. Sustained tolerance to peanut will be assessed at 36 weeks.